logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Regenxbio and AbbVie: A Good Reason for RGNX to Soar Today

Regenxbio and AbbVie in the NEWS Regenxbio ( RGNX ) stock soared today. The Company, along with AbbVie ( ABBV ), announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related...

Read More

September 13, 2021

0

Compugen: First Quarter Financial Results, Accomplishments and Future Plans

Compugen Updated Trial Data  Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology ( ASCO ) 2021 Annual Meeting Milestone rich 2021 to include data readouts from ongoing COM701...

Read More

May 13, 2021

0

Encouraging Results From Nektar's Product BEMPEG: NKTR-214 In Combination with the Checkpoint Inhibitor Nivolumab

Nektar Therapeutics Nektar Therapeutics ( NKTR ) announced the publication of Phase 1 clinical data for its immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) + nivolumab, in Cancer Discovery -  a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer...

Read More

May 22, 2020

0

The U.S. FDA Accepted Intellia Therapeutics IND Application of NTLA-5001 for Acute Myeloid Leukemia

Intellia Therapeutics IND Application of NTLA-5001 for AML is Accepted by the US FDA NTLA-5001 is Intellia Therapeutics ( NTLA ) first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer. It is an autologous T cell...

Read More

September 16, 2021

0

An Important Agreement Between Bristol-Myers Squibb and Agenus

Bristol-Myers Squibb and Agenus Agreement for AGEN1777 Bristol-Myers Squibb ( BMY ) and Agenus ( AGEN ) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to...

Read More

May 18, 2021

0

Why Sonoma Pharmaceuticals and Adaptimmune Stock Prices Skyrocketed

Sonoma Pharmaceuticals and MicroSafe Group, Dubai Sonoma Pharmaceuticals ( SNOA ) develops stabilized hypochlorous acid (HOCl) products for a wide range of applications including: wound care, eye care and dermatological conditions. Together with MicroSafe Group, Dubai, announced the receipt of...

Read More

May 29, 2020

0

Annovis Bio Inc: Very Encouraging Trial Results in Neurodegenerative Diseases

Annovis Bio Inc and Neurodegenerative Diseases Annovis Bio Inc ( ANVS ) , a clinical-stage drug platform company. This firm's focus is the treatment of neurodegenerative diseases. Annovis Bio Inc announced today new results from a double-blind, placebo-controlled study of...

Read More

May 21, 2021

0

Seagen Inc and Genmab Announce FDA Accelerated Approval for TIVDAK™ for Cervical Cancer

Seagen and Genmab Granted FDA Accelerated Approval for TIVDAK™ The U.S. FDA granted accelerated approval to Seagen Inc ( SGEN ) and  Genmab A/S ( GMAB ) product TIVDAK™ (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate ( ADC )...

Read More

September 21, 2021

0

Encouraging News from Cassava Sciences

Cassava Sciences Announces Top-Line Clinical Data for Simulfilam Cassava Sciences Press Release Today Cassava Sciences ( SAVA ) announced top-line clinical data today from a pre-planned interim analysis of an on-going open-label study with its drug candidate simufilam in patients...

Read More

September 22, 2021

0

Has the Time Come for Curis Inc to Flex Its Muscles?

Curis Inc IND Application Cleared by the US FDA Curis Inc ( CRIS ) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CI-8993, the first-in-class monoclonal anti-VISTA antibody. Continue reading...

Read More

June 10, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 118
  • 119
  • 120
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy